about
Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.Vitamin D and cancer.Differential expression of galectin 3 in solid cell nests and C cells of human thyroidEpidemiology of gastroenteropancreatic neuroendocrine tumours.Targeted therapy with kinase inhibitors in aggressive endocrine tumors.Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.The evolving field of kinase inhibitors in thyroid cancer.Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.Unintentional recurrent laryngeal nerve injuries following thyroidectomy: Is it the surgeon who pays the bill?Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal.In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia.Endocrine dysfunction in patients with Fabry disease.Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease.Spine abnormalities and damage in patients cured from Cushing's disease.Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease.Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study.Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidNephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure.Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission.Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.Radioiodide induces apoptosis in human thyroid tissue in culture.Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation.Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients.Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease.Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound.Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
P50
Q34073712-0FC3371C-2504-4E48-94AE-BBF633F14F1AQ34278228-82F9996F-B8F8-49E7-877E-024C6217D127Q35586610-FD97B029-EEB3-4C05-9DD4-E26C1145885CQ38098702-6479911B-E400-4E70-B3B9-E9991197EABBQ38107011-38BB906F-560E-457D-9B43-DE0327A85F74Q38169899-6A0AABCA-22FF-48E1-AC0E-CBD6690E5357Q38252863-56D93515-01A9-4F96-9E12-E9A6D90B753CQ38730927-D3A5F9A3-8B0D-4588-8D1E-8E5C6EFC41BBQ38789650-62E4E94C-FA9E-4DBC-B617-AE3DEDF4E854Q38852606-E6E2E55D-698E-4D07-9457-CBF66162C057Q39307659-265BC044-F3CF-460C-ACD6-D447CA6E9FA4Q42465056-64291631-E91D-4C76-9029-F7C353EFDBECQ42914109-65DAD83A-B770-44E0-BB5E-EB3FBD7CF941Q43037122-C94C4A66-2707-4C8D-95A1-C31BEC814C07Q43586008-BEBE4DC6-F4A6-4FF6-8BE9-8E03503EFC70Q43696898-F0C008ED-B007-4D79-832E-901B95C55B6AQ43776388-0336732B-9442-4407-B2DA-498DEFE2CA30Q43861000-ED8CFC96-C4D1-4A5B-A0A5-75DCAE091328Q43902744-48AF9A7C-E158-4F16-A49C-C155802FBE70Q44077760-48EA8CAA-9443-4C1E-AD2C-A4B4EE9A3EC3Q44077773-09F8BFD3-3730-4805-98CC-1EA2E4B52D1BQ44331759-6241ECFC-6963-4F4B-8937-E8AF11DDB674Q44336108-265EF360-8EB2-4157-810E-63F71CC43CBEQ44392879-5F19B435-796B-4BE2-9312-394862814BAFQ44427453-33D1A98A-BA3D-46D8-9C13-D1EAE0141E99Q44467027-AEB5BAD4-2DE7-4628-8C5C-A3324B3AA0DAQ45012482-CF3ABFF5-2598-4F2D-8907-5567E83B5EE3Q45859429-DDF3F1C7-0E58-4C3F-BBFF-351750902EFBQ45944006-2E897EDF-D28B-41E7-AFEF-515E6126E998Q46098368-30FAE647-2F85-44AF-8648-F9222FD25793Q46250367-83254D29-29AF-46F7-AA68-D29352482EDBQ46289029-A44A5B4B-454F-44A1-A340-BA525568E0F7Q46419679-22FC85BC-4FFA-44A2-BA56-E6E389F9EA87Q46527691-BF574BC7-C9BD-439B-922C-1FBB7D2FC7DEQ46591751-6003FCEE-2515-472E-94A6-DBD7EE565C8FQ46623269-683FEA66-DF55-4C46-9AE2-36387B3A8D65Q46713358-2A495047-83B9-43AA-ADF3-1126DB462C4BQ46808366-85EAC1C0-8C97-4FE3-84AC-36B71148A656Q46887081-86AA6BFE-F568-4D28-8927-D4C77F53DD38Q47833488-E99E74F9-E3E0-4133-BBDD-CA0A74D258BE
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Antongiulio Faggiano
@ast
Antongiulio Faggiano
@de
Antongiulio Faggiano
@en
Antongiulio Faggiano
@es
Antongiulio Faggiano
@nl
type
label
Antongiulio Faggiano
@ast
Antongiulio Faggiano
@de
Antongiulio Faggiano
@en
Antongiulio Faggiano
@es
Antongiulio Faggiano
@nl
prefLabel
Antongiulio Faggiano
@ast
Antongiulio Faggiano
@de
Antongiulio Faggiano
@en
Antongiulio Faggiano
@es
Antongiulio Faggiano
@nl
P227
P1053
K-7771-2016
P106
P21
P214
13152138516510980770
P227
1154454932
P31
P3829
P496
0000-0002-9324-3946
P7859
lccn-n2018184181